A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections
about
Systemic antibiotics for treating diabetic foot infectionsAntibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical woundsDelafloxacin: design, development and potential place in therapyDirect molecular versus culture-based assessment of Gram-positive cocci in biopsies of patients with major abscesses and diabetic foot infectionsEfficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.The potential role of nemonoxacin for treatment of common infections.Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.Frequent bacterial skin and soft tissue infections: diagnostic signs and treatment.Genetic Variation in TLR10, an Inhibitory Toll-Like Receptor, Influences Susceptibility to Complicated Skin and Skin Structure Infections.Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.TLR1, TLR2, and TLR6 gene polymorphisms are associated with increased susceptibility to complicated skin and skin structure infections.[Systemic therapy with antibiotics. Overview of important antibiotics in dermatology].Polymorphisms in cytokine genes IL6, TNF, IL10, IL17A and IFNG influence susceptibility to complicated skin and skin structure infections.
P2860
Q24187313-F8DBB98A-F429-4B74-BC02-E50BEC2FD3F6Q24202424-D5737452-8088-44DE-9646-D7A6FB424326Q34554381-2B9399B6-8FCE-42E1-826E-91B0A1ED4ACEQ35983355-CB4DAC00-76FF-459D-B336-F95A7EA70A30Q36592698-BA58690B-AFC1-4E38-8519-94A58A368F0BQ36997690-31EB175E-AE2C-4A2A-AAE7-CA89ED59162AQ37842543-EABCA6A6-C199-4844-9D05-2B6646FDCD36Q38129444-11B06A14-9872-429D-B74A-3209052DBFE9Q39382608-8B69103A-AF64-4DC9-BA97-CF4369C07194Q40154168-1110AFB7-D2F2-436D-B653-004F288C436CQ41304611-871CFB7A-2ABD-4591-B851-2ABC71F80230Q41534755-63D03415-0804-48B0-968D-40003FD89349Q42229180-74744195-512F-4B82-B930-307DE5244D0AQ52767037-B8200B98-82C1-4B2E-84D7-8A94A19DAD56Q54285526-31458CA0-56F1-409E-8429-9D4F140ECDDC
P2860
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized trial of the effi ...... and skin structure infections
@ast
A randomized trial of the effi ...... and skin structure infections
@en
type
label
A randomized trial of the effi ...... and skin structure infections
@ast
A randomized trial of the effi ...... and skin structure infections
@en
prefLabel
A randomized trial of the effi ...... and skin structure infections
@ast
A randomized trial of the effi ...... and skin structure infections
@en
P2093
P2860
P356
P1476
A randomized trial of the effi ...... and skin structure infections
@en
P2093
Barbara Hampel
Dilip Nathwani
Inge C Gyssens
Jeff Alder
Matthew Dryden
Peter Kujath
Peter Reimnitz
Pierre Arvis
P2860
P304
P356
10.1093/JAC/DKR344
P407
P50
P577
2011-09-06T00:00:00Z